Plumas (NASDAQ:PLBC) reported quarterly earnings of $0.96 per share. This is a 12.94 percent increase over earnings of $0.85 per share from the same period last year.
Bicycle Therapeutics Announces First Patient Dosed In BT8009 Phase II Expansion Cohorts And Provides Program Update
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from